To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

The requested reference [e375d7b6fff951315d44067ec2098953843c1076] no longer exists in our database. It has been replaced by the current reference: [457cfc1e6bc4d920a1a59ead4ce5f73cb4432476]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Results will be submitted, however please note that data are not yet available for all serology outcome measures. This will be a Phase 2/3, randomized, placebo-controlled, observer-blind study evaluating the safety, tolerability, and immunogenicity of 30 µg of BNT162b2 or placebo administered in 2 doses, 21 days apart, in approximately 350 healthy pregnant women 18 years of age or older vaccinated at 24 to 34 weeks\' gestation. Participants will be randomized 1:1 to receive BNT162b2 or placebo (saline).
Epistemonikos ID: 7b30696095d820c15d7fe774a7d767821f46001d
First added on: Feb 16, 2021